Recent studies have characterized the extensive somatic alterations that arise during cancer. However, the somatic evolution of a tumor may be significantly affected by inherited polymorphisms carried in the germline. Here, we analyze genomic data for 5954 tumors to reveal and systematically validate 412 genetic interactions between germline polymorphisms and major somatic events, including tumor formation in specific tissues and alteration of specific cancer genes. Among germline-somatic interactions, we find germline variants in RBFOX1 that increase incidence of SF3B1 somatic mutation by eight-fold via functional alterations in RNA splicing. Similarly, 19p13.3 variants are associated with a four-fold increased likelihood of somatic mutations in PTEN. In support of this association, we find that PTEN knock-down sensitizes the MTOR pathway to high expression of the 19p13.3 gene GNA11. Finally, we observe that stratifying patients by germline polymorphisms exposes distinct somatic mutation landscapes, implicating new cancer genes. This study creates a validated resource of inherited variants that govern where and how cancer develops, opening avenues for prevention research.
Introduction
We obtained common germline variants and somatic tumor mutations for 6, 908 patients from the TCGA Research Network (20). We restricted our analysis to germline variants present at minor allele frequencies of 1% or higher in this patient group, resulting in 706,538 autosomal single nucleotide polymorphisms (SNPs) organized into ~1.6 million haplotypes (Fig. 1A) . Both SNPs and haplotypes were studied, as the two marker types have complementary power to detect common and rare disease-associated variants, respectively (21-23).
Examination of patient SNP profiles showed evidence of population substructure (24), even among the majority of patients who self-identified as European ancestry (Fig. S1A) . Of these patients, we retained 4,165 who also clustered tightly with Europeans from the HapMap III reference population (25) (discovery cohort, Fig. 1B ). For later replication of our findings, we used a validation cohort consisting of 1,789 additional TCGA patients for which full data (tissue type and somatic alterations) became available only after the start of our study (Fig. S1B, 
S1C).

Associations between germline and tumor site of origin
We first sought to identify germline markers associated with the site at which the tumor develops, i.e. incidence of tumors of a particular tissue type. Previous studies have focused on individual tumor types in isolation, thus it remains unclear to what extent cancer-associated alleles are general versus site specific.
All tumors of a particular type were compared to all other types pooled; separate comparisons were performed for each of the 22 TCGA tumor types. SNP or haplotype markers were selected as initial candidates if their p-values of association were less than the "suggestive" threshold commonly used in GWAS (26): 1x10 -5 by Fisher's Exact Test, corrected for the number of tumor types assessed. Different tumor types were collected at different times by TCGA; to minimize false positive associations due to such batch effects, we removed markers displaying strong association with batch or plate (Fig. S2 ) and used genomic control to adjust for inflated p-values (Fig. S3) . In cases in which multiple tumor types were each weakly associated with a genotype, these were combined for testing for stronger association as a group. All candidate associations were then tested in the validation cohort, and empirical false discovery rates were estimated using matched numbers of random associations.
By this procedure we identified 916 markers of potential interest, 395 of which could be replicated at an empirical FDR < 0.25 ( Fig. 1C, 2A ; Table S1 ).
Additional markers at each locus were imputed to provide a more complete view of the association. While all TCGA patients have been diagnosed with some type of cancer, these germline markers provide predictive information about where the tumor develops.
As an example, markers at locus 8q24.13 were identified for their specific and significant association with breast cancer (P < 2×10 -10 , Fig. 2B ), which was reinforced by a second finding of association with age of breast cancer onset (Fig. 2C ). While this region had not previously been implicated in cancer predisposition, it had been reported to harbor frequent somatic amplifications in breast cancer cell lines (27) . In addition, breast tumors overexpressing genes in this region are associated with shorter time to recurrence (28-31). Among the many other loci associated with tumor type, we identified a SNP at 13q14.2 that falls into an intron of the tumor suppressor RB1 and is associated with multiple tumor types, and a SNP at 11q22.3, a region encoding the cancer genes DDX10 and ATM, that is associated with breast cancer (Table S1 ). Epigenetic silencing of DDX10 was recently reported in ovarian cancer (32), and rare germline coding variants in ATM have previously been reported in familial breast cancer (33).
To examine the correspondence of this TCGA analysis with previous GWAS of cancer, we analyzed 557 cancer-associated SNPs recorded in the NHGRI GWAS Catalog (26). Most of these previous SNPs had been identified based on an increase in risk for developing cancer as compared to non-diseased controls, whereas the SNPs identified in our study are based on an increased prevalence of tumors of one particular tissue as compared to other tissues.
Despite this difference, the previously published markers of cancer risk had substantial correspondence to the markers associated with tumor site, with the strongest signal seen for approximately 15 markers (Fig. 2D, Fig. S4A-S4D , Table S2 ). The loci validated by both types of study can be prioritized as a set of clearly reproducible cancer risk factors that are also specific to tissue of origin.
Even where the new associations recapitulate a previously reported cancer locus, new insights may be gained, as illustrated for the thyroid cancer locus 9q22.23 (34,35) (Fig. 2E) . SNP rs1867277 at this locus, in the promoter region of the FOXE1 transcription factor, was previously reported to be the cause of association; the minor allele was shown to recruit the USF1/USF2 transcription (Fig. 2F) . This discrepancy in FOXE1 expression levels may arise from performing the analysis in patient tumors, whereas the previous report was based on experiments in cancer cell lines, and in part because risk in this region is driven by at least two distinct haplotypes that may affect the expression of different genes (39,40).
Interestingly, targeted overexpression of FOXE1 was not in itself capable of causing thyroid cancer in mice (41) , suggesting other genes in this region may play a role. Thus, re-analysis of this locus using genotype and mRNA expression from the TCGA suggests that its role in thyroid cancer may be more complex than previously appreciated.
Associations between the germline and somatic alteration of specific genes
We next sought to identify associations between inherited germline variants and the occurrence of somatic mutations in particular cancer genes. We hypothesized that germline background could generate a context in which a loss or gain of function event in a particular gene could be advantageous to a tumor. As loss or gain of function is commonly achieved through DNA mutation or amplification/deletion, we considered both somatic mutation and somatic copy number changes in our analysis. We used a previously published set of 138 cancer genes which had been compiled based on a strong signal of positive selection for subtle somatic mutations (SSMs, i.e. point mutations, insertions or deletions) or CNVs in tumors (2) . Such evidence of positive selection suggests that the alterations affecting these genes are likely to be enriched for functional drivers. Indeed, genes under positive selection in cancer exhibit a bias toward mutations predicted to interfere with protein activity (42, 43) . Because these genes play a central role in many cancers, we expected that germline loci associated with their alteration status in tumors would provide insight into specific biological contexts that influence which cancer genes most effectively promote tumor growth and survival. For the most frequently mutated genes in this set, such as TP53 which is altered in approximately 35% of TCGA tumors, we estimated that we had 80% statistical power to detect changes in mutation rate of ≥ 1.8-fold (Fig. S5A) . For genes near the median mutation frequency in this set, such as BRCA1 which is altered in ~3% of tumors, we were powered to detect changes in mutation rate of ≥ 3.0-fold.
Associating testing identified a total of 62 associations between germline markers and specific cancer genes, of which 17 were found to replicate in the validation cohort at an empirical FDR < 25%, and of which 35 were deemed of potential interest (empirical FDR < 50%; Fig. 1C rates for cancer genes tended to increase with the number of minor alleles at the germline locus, with the largest increases coinciding with the least frequent germline alleles (Fig. 3A-C) . The effect sizes were quite large, corresponding to increases in mutation frequency of 1.8-to 14.8-fold (Fig. 3A) , and were well correlated between the discovery and validation cohorts (r=0.43, P < 0.01; Fig.   S5B ). Such large effects linked to common SNPs are particularly striking in comparison to typical GWAS, where effect sizes tend to fall beneath 2-fold (13).
For example, a haplotype on 15q22.2 resulted in a 14-fold increased chance of acquiring a CNV affecting GNAQ.
In what follows, we further investigate validated germline-cancer gene associations at 16p13.3 and 19p13.3 as instructive examples. At each of these loci, one or more genes encoded at the germline locus participates in the same biological pathway as the somatically-mutated cancer gene (Fig 3A,C associations labeled in red).
Intronic SNP in RBFOX1 enables somatic mutation of SF3B1 to affect splicing
In one noteworthy connection between germline and somatic gene mutations, we observed a haplotype at 16p13.3 that was associated with a markedly increased risk of somatic mutation in SF3B1, encoding a component of the U2snRNP spliceosome (Fig. 4A , a striking >8-fold increase in mutation rate under the homozygous minor allele). The most strongly associated haplotype encompassed an enhancer in the fourth intron of RBFOX1 (Fig. 4B) involved in splicing, which influences the inclusion or exclusion of exons in alternatively spliced isoforms (44) . This suggested a model whereby the germline configuration of RNA splicing, linked to variation in RBFOX1 expression, modulates the sensitivity of RNA splicing to subsequent somatic mutations in the U2 spliceosome (Fig. 4C) .
In support of this hypothesis, we first found that the minor allele at this locus tends to substantially increase RBFOX1 expression, especially in homozygotes (Fig. 4D , normalized across tissue types). Next, we investigated how the germline state of RBFOX1, somatic mutation of SF3B1, or the combination of both of these factors impacted RNA splicing patterns in TCGA patients. In patients with the major RBFOX1 allele, SF3B1 mutation had minimal effect on splicing; In contrast, in patients with the minor allele, SF3B1 mutation led to changes in splicing patterns within a number of transcripts (Fig. 4E) .
Altogether, we identified splice junctions in 11 genes for which there were significant increases or decreases in the fraction of cryptic transcripts, dependent on SF3B1 somatic mutation (Fig. 4E) . Such genes include those driving cellular proliferation and metabolism (ribosomal subunits, protein turnover) as well as YBX1, a regulator of alternative splicing. A functional relationship between RBFOX1 germline status and SF3B1 somatic mutation was also supported by statistical modeling, which revealed a significant interaction of these two factors in predicting the overall fraction of cryptic transcripts in a patient (P < 0.04).
Research. (Fig. 5A) . We noted that two genes at this locus, GNA11 and STK11, function in the PIK3CA/mTOR signaling pathway in which PTEN plays a major repressive role (Fig. 5B) . In particular, GNA11 can act as an oncoprotein by activating mTOR signaling (45) , whereas STK11 inhibits mTOR activity downstream of PTEN (46,47). The convergence of these three proteins on the mTOR pathway suggested a model in which the minor allele of 19p13.3 affects mTOR signaling, conferring sensitivity of this pathway to later somatic mutation of PTEN.
In support of this hypothesis, we observed that mRNA expression of GNA11 was higher in the presence of the minor 19p13.3 allele in a majority of tumors types examined (P < 0.05, one-sided Mann Whitney Test with multiple testing correction) (Fig. 5C) . To investigate the impact of changing GNA11 expression, we next placed transcription of GNA11 under exogenous control in HEK293T cells and measured the relationship between GNA11 expression level and mTOR signaling activity. Increases in GNA11 mRNA led to corresponding increases in mTOR signaling in wild-type cells; however, this effect was greatly magnified by PTEN knockdown (Fig. 5D) . Interestingly, we observed that STK11 loss of function (mutation or deletion) was significantly more likely in the presence of a GNA11 gain of function event (mutation or amplification) (OR:
2.87, P < 1x10 -12 STK11 might also interfere with GNA11 activation of mTOR signaling, since like PTEN it serves as a repressor of mTOR signaling. Indeed, we observed that the increase in mTOR signaling due to GNA11 was greatly magnified under STK11 knockout (Fig. 5E ), just as we had observed for PTEN knockdown. Although further work is needed, these findings lend support to a model by which alterations at locus 19p13.3 increase the activity of GNA11, which in turn, increases the selective advantage provided by PTEN inactivating mutations during tumorigenesis.
Given this particular sensitivity of GNA11-driven mTOR signaling to STK11 knockout, we hypothesized that GNA11 may also act upstream of STK11.
Indeed, GNA11 expression was sufficient to increase the level of STK11 protein phosphorylation with a concomitant increase in phosphorylation of AMPK (Fig.   5F ), a direct target of STK11 (Fig. 5B) (48) . These findings suggest that GNA11 increases mTOR function while indirectly stimulating AMPK-based inhibition of mTOR via STK11 (Fig. 5B dotted line) .
Tumor classification by germline identifies new gene mutation landscapes
Since we had identified 28 germline loci that increase the occurrence of somatic alterations in well-known cancer genes, we hypothesized that these same loci might influence mutation rates of other genes not previously linked to cancer. To explore this idea, we used MutSigCV (49) to identify all genes mutated more frequently than expected when grouping TCGA patients in the discovery cohort not by tissue, as has been performed successfully many times in the past (49) but according to the state of their germline at each of the 28 loci. This analysis identified 20 additional genes that had a significantly higher somatic mutation rate than expected when analyzed in a specific germline context (Fig. 6) . Some genes had an elevated mutation rate in the presence of the minor allele ( Fig. 6 purple blocks), while others were only mutated with the homozygous major allele ( Fig. 6 green blocks ). An elevated mutation rate relative to the background expectation is a signature of positive selection; thus this approach has the potential to identify genes under positive selection in cancer on a particular genetic background.
Of the 20 genes identified by MutSigCV, fifteen had not previously been identified as frequently mutated in any TCGA or ICGC cancer genome study.
Evidence suggests that several of these genes could be relevant to carcinogenesis: for instance, CD86 plays a role in the early T-Cell response (50), TPTE encodes a phosphatase with very high sequence similarity to the known tumor suppressor PTEN (51) , and DEFB115 is often co-mutated with protein kinase C isozymes PRKCG, PRKCH and PRKCQ which have been implicated as tumor suppressors (52) . Thus mutation analysis based on cohorts defined by genotype, rather than tissue, can provide a powerful strategy to identify novel genes in cancer. role of inherited variation in adult cancer, with a view towards next-generation risk assessment and prevention (53) . Here, we have described a genome-wide analysis of germline-somatic interactions, based on the availability of germline genotypes and somatic phenotypes for most TCGA patients. We found evidence that genetic background can influence the somatic evolution of a tumor in at least two ways: in determining the site of tumorigenesis; and by modifying the likelihood of acquiring mutations in specific cancer genes. The ability to analyze matched genotypes, somatic genome alterations, and mRNA expression profiles enabled us to not only identify germline-somatic genome linkages but also to investigate which genes at a given locus are impacted transcriptionally and thus may mediate the effects of germline variants. Moreover, by grouping tumor samples according to the state of inherited genetic variants, it was possible to discover recurrent somatic mutations that were not identifiable by any previous cancer analysis, highlighting novel cancer gene candidates.
Collectively, this resource of germline-somatic interactions in cancer will generate many testable hypotheses about the molecular mechanisms underlying adulthood cancer risk. Interactions that are most readily interpreted are those for which genes at the germline locus function in the same biological pathway as the gene that is somatically altered. For example, a locus associated with PTEN mutation encoded two cancer genes in the same pathway, GNA11 and STK11; all three of these genes regulate growth signaling via mTOR (Fig. 5) . We were able to show experimentally that both STK11 and PTEN interfere with GNA11 activation of mTOR, suggesting that germline variants increasing the activity of both genes regulate alternative RNA splicing (Fig. 4) . Further investigations showed that SF3B1 mutation is associated with significant differences in cryptic RNA splicing, exclusively in individuals with the minor allele. We expect that further analysis of the many additional germline-somatic interactions reported in this resource will provide clues about the underlying molecular relationships that promote cancer.
Some frequently altered cancer genes, such as TP53 and PIK3CA, were not found to be influenced by common germline variants. This result is somewhat puzzling since, due to their frequent mutations in TCGA, our analysis was highly powered to find germline associations with these genes (Fig. S5A) . One explanation is that the mutation of these genes is so critical to cancer that it provides a selective advantage to tumor cells regardless of germline background.
Another possibility is that germline interactions take place with specific mutation sites within the gene, but not with the gene as a whole, as was previously reported for germline control of JAK2 mutation (16).
An important question is to what extent germline variants, including the ones identified here, can impact precision medicine. Thus far, translating cancer GWAS to the clinic has been challenged by the generally small effect sizes of risk variants identified (13) . Here, among individuals with cancer, we identified germline alleles that had very large effects on the progression of later somatic events (e.g. a 15q22.2 allele that increases somatic alteration of GNAQ by >10- fold, Fig. 3A) . Moreover, a number of the reported associations were with minor germline alleles that are quite common in the human population (e.g. markers at 10p15.1 or 18q21.2 at frequencies >30%, Fig. 3B ), or involve cancer genes with very high somatic mutation frequencies, such as PTEN which is mutated in >60% of some cancer types (54) . Such interactions may be of particular interest for their ability to stratify cancer patients, although the true utility of these large effect sizes in a multigenic disease setting remains to be determined. Future studies of germline associations with other clinically important somatic phenotypes, such as site of metastasis, measures of aggressiveness, or therapeutic response, may also reveal large networks of informative interactions. Ultimately, the influence of many germline variants on specific somatic changes in tumors suggests it might be possible to anticipate key events during tumor development, enabling a preventative rather than reactionary approach to therapy.
Materials and Methods
Two phase study
Data were obtained from the TCGA and divided into a discovery and a validation cohort based on availability of all data types before or after 05/2014. Distribution of tumor types in each cohort is shown in Fig. S1C . Assignment of each sample to discovery or validation cohorts is provided in Table S4 . We acquired genotype, clinical, copy number and somatic mutation data for all available samples.
Human genome assembly GRCh37/UCSC hg19 coordinates were used for all genomic data. 
Genotypes
Normal (non-tumor) level 2 genotype calls generated from Affymetrix SNP6.0 array intensities using the BirdSuite software (55) were retrieved from the TCGA data matrix. In these files, each SNP was annotated with an allele count (0=AA, 1=AB, 2=BB, -1=missing) and a confidence score between 0 and 1. Genotypes with a score larger than 0.1 (corresponding to an error rate > 10%) were set to missing and the data were reformatted with PLINK v1.9 (56) .
Somatic Phenotypes
Information on tumor type was available for all samples. Exome-wide profiles of somatic DNA mutations and genome-wide CNVs were accessed from the Broad Firehose Analysis Pipeline (57) (April 16, 2014 release) (Fig. S1B) . Somatic mutations for 1099 validation samples were obtained using MuTect (58) and Somatic Indel Detector from GATK release 2.2-2 (59).
In addition to TCGA CNV calls, we used the PennCNV (v1.0.3) Affymetrix pipeline to call CNVs using default parameters (60) . The Affymetrix Power Tools software package was used to generate signal intensity data from raw CEL files.
PennCNV was used to split the signal intensity files by individual, generate CNV calls, merge adjacent CNVs, and annotate CNV calls with UCSC hg19 knownGene annotation. CNV and somatic mutation rates were used as covariates for statistical modeling.
Somatic mutation rate was modeled by the nonsynonymous mutations per MB reported in the Firehose MutSig analysis (49) and CNV rate was modeled as the number of CNVs per sample, approximated by the number times each sample appeared in the focal_input.seg.txt file from the Firehose GISTIC2.0 analysis (62) . In each case, values could be assigned to most tumor samples (Fig. S1B) .
TCGA Discovery Phase
We discarded 322 SNPs with probe names that did not match the hg19 UCSC genome browser Affymetrix track (track: SNP/CNV Arrays, table:snpArrayAffy6).
Allele counts were converted to alleles using the definitions in metadata distributed with Birdsuite and negative strand genotypes were flipped to the positive strand using PLINK.
European ancestry samples were identified using the TCGA metadata (Fig.   S1A ). Genotypes were filtered with PLINK to remove SNPs with call rate < 95%, SNPs with minor allele frequency (MAF) < 1% and individuals with genotype coverage < 95%. Additional samples were dropped due to ambiguous or conflicting gender assignment and unexpectedly high or low rates of ) were excluded from further analysis (Fig. S2) .
TCGA Validation Phase
Affymetrix SNP6.0 genotypes for 1789 validation samples were filtered for call rate, coverage and minor allele frequency. SNPs not present in the discovery set were removed and SNPs missing from the discovery set were imputed using PLINK. Validation set genotypes were phased using Beagle v3.3.2, and haplotypes markers were assigned based on agreement of phased SNP sequences with best associated SNP sequence for each discovery set haplotype as determined by the cluster2hap utility and as previously described (65) . 
Population Stratification
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Haplotype Inference
Haplotypes were inferred using Beagle software v3.3.2 (67), and encoded as binary markers using the psuedomarkers.jar java utility (parameters: edgecount=60 and othercount=10), resulting in 1598830 haplotype markers.
Power Calculations
Power to detect association with gene alteration status was estimated using the Genetic Power Calculator (68) via the ldDesign R package (69) . Empirical estimates of case-control ratio were modeled by the number of TCGA samples harboring alterations in each gene. Allele frequency and prevalence were set to 0.01. D' was set to 1 and the same frequency was used for the marker and quantitative trait locus, simulating the best-case scenario where the causal SNP is genotyped.
Research. 
Discovery Phase Testing
When testing for marker association with tumor type, samples were partitioned using a one versus rest strategy. For marker association with somatic alteration status at each of the 138 cancer genes, samples were partitioned into two groups based on the presence or absence of a somatic alteration (Fig. 1A) .
Association testing between all marker-gene and marker-tumor type pairs was performed using a two-sided Fisher's Exact test with PLINK. This test is not affected by class imbalance, which occurs for most phenotypes in this study.
Candidate associations were selected based on the "suggestive" GWAS significance threshold, adjusted by the number of phenotypes tested (1x10 -5 /22
for primary tumor type and 1x10 -5 /138 for mutation status of cancer genes). Pvalues were adjusted for inflation using genomic control (Fig. S3, S6) . Because allelic tests are biased for SNPs violating Hardy Weinberg Equilibrium, candidate associations were subjected to permutation to obtain empirical p-values; somatic alterations were permuted across samples 1x10 8 times to generate an empirical null distribution capable of providing a p-value with a resolution of 1x10 -8 .
Multi-tumor association
To gain power to identify SNPs associated with multiple tumor types, tumors with correlated ORs were tested for association as a group. Specifically, loci receiving at least one weak but insignificant association (P < 0.05) were reevaluated by grouping correlated tumor types. All tumors at the locus with an OR > 1.2 were grouped and a Fisher's Exact Test was performed to determine their combined OR and P-value. This joint P-value was compared to an empirical distribution obtained by permuting tumor type label 1000 times, grouping tumor types with OR > 1.2 and repeating the Fisher's Exact test. Markers were selected for validation if they were among the top 5 most significant tests after permutation, and had a combined OR > 1 and a P-value < 1x10 -5 .
Controlling for covariates
Firth's penalized logistic regression (R logistf package) (70) was used to control for covariates, including population substructure (1 st two principal components PC1 and PC2), individual-specific somatic mutation and/or copy number alteration rates, and gender. For associations with cancer genes, we also controlled for primary tumor type. The Wald test was used to reject the hypothesis that the slope contribution of the genotype in the fitted model was 0 (i.e., that the genotype does not provide information about the phenotype) in the presence of covariates.
Validation
For both gene alteration status and tumor type associations, validation testing was performed using a one-sided Fisher's Exact test consistent with the odds ratio observed in the discovery screen. Candidate associations achieving an empirical false discovery rate (FDR) < 0.5 were considered to be of potential interest are listed in Tables S1 and S3 . We considered a marker to have "validated" at an empirical FDR < 0.25. These associations are visualized as a 
Empirical false discovery rate estimation
For each candidate marker-phenotype pair carried forward for validation testing, phenotype labels were permuted 10,000 times. Each of these 10,000 sets of permutated marker-phenotype pairs was then evaluated in the validation cohort.
The expected number of false discoveries at a particular significance threshold was estimated as the mean number of marker-phenotype pairs detected at that threshold across the 10,000 permutations. The empirical false discovery rate was estimated as the ratio of false discoveries to the total number of candidates detected at a particular significance threshold. Empirical FDRs were estimated at significance threshold intervals of 0.05.
MutSigCV Analysis
MutSigCV version 1.4 (49) with default parameters and configuration files was used to identify genes with an elevated mutation rate on each germline background. Discovery phase samples were divided into two groups: those with one or more copies of the minor allele, and those with none. MutSigCV was run separately on both groups to identify genes that were mutated at higher frequency than expected according to its gene-specific background mutation model.
Research. (71) . To determine a pan-cancer relationship between gene expression and genotype, log 2 expression was regressed on minor allele count and tumor type. Significance of effect size was determined by first regressing expression on primary tumor type alone. Variance due to tumor type was removed by summing the expected value over all samples and the residuals after regressing on tumor type. Effect sizes were estimated using a one sided t-test to evaluate the difference in distributions for samples with one or more copies of the minor allele versus samples homozygous for the major allele. T-tests were performed when at least 5 samples were present in both groups.
Alternative Splicing Analysis
TCGA RNASeq data for 95 samples with SF3B1 mutations and 105 controls (Table S5 ) were processed as previously described (72) . The percentage of cryptic reads at each splice site across the genome was calculated for each patient. Only splice sites in the top 85 th quartile of coverage were considered for the analyses. Percentages were log transformed and averaged across patients with matching genotypes in order to determine the variation in splicing due to the minor allele and SF3B1 mutation status. Specifically, the number of sites that were differentially spliced between WT and SF3B1 mutant tumors was determined for individuals with one or more copies of the minor allele, and In order to control for the effect of sample size differences when partitioning tumors on germline genotype on identifying differentially spliced junctions, samples with the major allele were down-sampled 1000 times. A two-sample ttest was used to determine whether cryptic splicing occurred at the same frequency for samples with the minor allele and without an SF3B1 mutation as compared to all other samples. To correct for any biases, the observed genotypes were randomly re-assigned 10,000 times and the two-sample t-test reperformed.
Imputation, Locus Annotation and Visualization
A gene was considered to be in cis with a germline marker if it was encoded within 1MB of the marker. Coordinates of promoters, exons and introns were determined from Gencode V19 basic obtained from the UCSC Genome Browser locus and NHGRI cancer GWAS SNPs was assessed using the SNAP server (76) . The NCBI Genome Decoration Page was used for ideogram construction.
Published cancer-associated SNPs from the NHGRI GWAS Catalog, and additional SNP markers at loci implicated in this study were imputed using the Michigan Imputation Server (77) (1000 genomes Phase 1v3 reference, Shapeit2). Imputed markers were used for visualizing loci using Locuszoom Software (78) . For LocusZoom plot construction, we used default recombination rates, gene locations and NHGRI catalog data. LD values were generated from the 1000 Genomes 2012 European population, and promoter and enhancer regions were determined as described above.
Cell lines
HEK293 cell lines were obtained from the American Type Culture Collection (ATCC) in 2015 and stored in liquid nitrogen vapor. Cells were authenticated using short tandem repeat (STR) fingerprinting within 6 months of freezing.
HEK293 cells for the current study were thawed from this stock. (purchased from Addgene#62988). STK11 knock out was confirmed by western blot (Fig S7A) . The corresponding sgRNAs were designed using the CRISPR design website following published protocols (79). Cells were transfected with the CRISPR construct and selected for 3 days using puromycin then replaced by fresh medium to maintain the growth of the cell. Mass culture of cells were confirmed to lack STK11 protein expression by western blotting. (Fig S7B) .
PTEN knock down and GNA11 expression
Western blotting
Immunodetection was carried out using antibodies from Cell Signaling 
control. GNA11 (D-17) was detected using a primary antibody from Santa Cruz Biotechnology (sc-394). Secondary horseradish peroxidase-linked goat antirabbit IgG antibodies were obtained from Southern Biotech.
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